2,203 reports of this reaction
14.5% of all GLECAPREVIR AND PIBRENTASVIR reports
#2 most reported adverse reaction
HEADACHE is the #2 most commonly reported adverse reaction for GLECAPREVIR AND PIBRENTASVIR, manufactured by AbbVie Inc.. There are 2,203 FDA adverse event reports linking GLECAPREVIR AND PIBRENTASVIR to HEADACHE. This represents approximately 14.5% of all 15,159 adverse event reports for this drug.
Patients taking GLECAPREVIR AND PIBRENTASVIR who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a frequently reported adverse event for GLECAPREVIR AND PIBRENTASVIR, accounting for a significant proportion of all reports.
In addition to headache, the following adverse reactions have been reported for GLECAPREVIR AND PIBRENTASVIR:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 2,203 FDA reports for GLECAPREVIR AND PIBRENTASVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 14.5% of all adverse event reports for GLECAPREVIR AND PIBRENTASVIR, making it one of the most commonly reported side effect.
If you experience headache while taking GLECAPREVIR AND PIBRENTASVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.